Risultati della ricerca - Savvas Toumanidis
- Mostra 1 - 4 risultati su 4
-
1
-
2
-
3
Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies di Efstathios Kastritis, Μαρία Ρούσσου, Maria Gavriatopoulou, Magdalini Migkou, Despina Kalapanida, Constantinos Pamboucas, Elisavet Kaldara, Argyrios Ntalianis, Erasmia Psimenou, Savvas Toumanidis, Anna Tasidou, Evangelos Terpos, Meletios Α. Dimopoulos
Pubblicazione 2015Artigo -
4
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone di Efstathios Kastritis, Αchilles Anagnostopoulos, Μαρία Ρούσσου, Savvas Toumanidis, Constantinos Pamboukas, Magdalini Migkou, Anna Tassidou, Irini Xilouri, Sossana Delibasi, Erasmia Psimenou, S. Mellou, Evangelos Terpos, J. Nanas, Meletios Α. Dimopoulos
Pubblicazione 2007Artigo
Strumenti per la ricerca:
Soggetti correlati
Internal medicine
Medicine
Ambulatory
Ambulatory blood pressure
Blood pressure
Body mass index
Bortezomib
Cardiology
Dexamethasone
Gastroenterology
Multiple myeloma
Surgery
White coat hypertension
AL amyloidosis
Amyloidosis
Antibody
Circadian rhythm
Creatinine
Dialysis
Diastole
Discontinuation
Essential hypertension
Heart rate
Immunoglobulin light chain
Immunology
Lenalidomide
Masked Hypertension
Melphalan
Obesity
Oncology